Treatment of hereditary autoinflammatory diseases

Area of Science:

• Genetics and Immunology
• Rheumatology
• Pediatric Medicine

Background:

• Hereditary autoinflammatory diseases (HAIDs) are a group of rare genetic disorders characterized by recurrent episodes of unprovoked inflammation.
• Key HAIDs include Familial Mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndromes (CAPS), and mevalonate kinase deficiency (MKD).
• Current treatment strategies for HAIDs have evolved, necessitating a review of recent therapeutic advances.

Purpose of the Study:

• To summarize recent advancements in the treatment of FMF, TRAPS, CAPS, and MKD.
• To discuss the implications of new findings for patient care and future clinical research in HAIDs.

Main Methods:

• Review of recently published studies on the treatment of FMF, TRAPS, CAPS, and MKD.
• Analysis of treatment efficacy, dosing, and patient response.

Main Results:

• Interleukin (IL)-1 blockade demonstrates significant efficacy across various autoinflammatory conditions, with younger patients often requiring higher doses.
• Colchicine remains the primary treatment for FMF, with IL-1 blockade serving as an effective alternative when colchicine fails.
• IL-1 blockade is well-tolerated and effective in CAPS, while its efficacy is also noted in TRAPS and MKD, though NSAIDs and corticosteroids may suffice for some patients.

Conclusions:

• While IL-1 blockade shows promise for HAIDs, robust evidence primarily exists for CAPS and FMF.
• Larger prospective trials are essential to establish definitive treatment guidelines, particularly for MKD, TRAPS, and colchicine-resistant FMF.
• Current therapeutic approaches for many HAIDs are informed by limited, retrospective data, highlighting the need for further research.